Overview

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Status:
Completed

Trial end date:
2020-01-30

Target enrollment:

Participant gender:

Summary

The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of switching to tenofovir alafenamide (TAF) versus continuing tenofovir disoproxil fumarate (TDF) in virologically suppressed adults with chronic hepatitis B virus (HBV) infection.

Phase:

Phase 3

Details

Lead Sponsor:

Gilead Sciences

Treatments:

Tenofovir